We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Tolerability of ALK Grass Tablet in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00310453
Recruitment Status : Completed
First Posted : April 4, 2006
Last Update Posted : May 4, 2006
Information provided by:
ALK-Abelló A/S

Brief Summary:
The purpose of this trial is to assess whether the ALK Grass tablet treatment is safe to use in children aged 5-12 years

Condition or disease Intervention/treatment Phase
Allergy Biological: ALK Grass tablet Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of ALK Grass Tablet in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)
Study Start Date : March 2006
Estimated Study Completion Date : May 2006

Primary Outcome Measures :
  1. Assessment of safety by recording of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Grass pollen induced rhinoconjunctivitis
  • Boys and girls, 5-12 years of age
  • Positive skin prick test to grass pollen

Exclusion Criteria:

  • Severe asthma
  • Previous treatment with immunotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00310453

Servicio de Alergia, Hospital del Niño Jesús
Madrid, Spain, 28040
Sponsors and Collaborators
ALK-Abelló A/S
Study Director: Kim Simonsen, MD ALK-Abelló A/S, Boege Alle 6-8, 2970 Hoersholm, Denmark

ClinicalTrials.gov Identifier: NCT00310453     History of Changes
Other Study ID Numbers: GT-09
First Posted: April 4, 2006    Key Record Dates
Last Update Posted: May 4, 2006
Last Verified: May 2006